Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
NYSE:ABBV
AbbVie Inc. (ABBV)
217.00
+0.51 (0.24%)
as of Jun 18, 2026, 11:37:08 pm Market Open.
205 watching
Financials 
Technical Analysis 0
DON'T BUY
A good pharma, much larger after buying Allergan. They were spun off years ago from another company because major drug, Humira, was a cash cow. Because Humira has become 60-65% of all revenues, AbbVie smartly bought Allergan (Botox). Now, Humira amounts to 45% of revenues, and Humira went off-patent last year. A few big drugs are trying to fill that hole. He owned this before, but feels it's too risky now.
0
BUY
BMY and AbbVie The line is blurred between biotech and pharma. He likes both spaces and both stocks. Aging demographics means more and more drugs. Both are have solid valuations. They pay income but also offer capital appreciation.
Jim LebenthalOwned
0
BUY
He owns it for the dividend, pricing power and it has recreated after several missteps. Definitely holding this.
Joe TerranovaOwned
0
BUY
Reported a mix quarter today. Though shares are down today, it's still up 5% YTD. AbbVie re-affirmed guidance. She wouldn't read too much into the quarter.
Bryn TalkingtonOwned
0
BUY
Healthcare is his favourite defensive sector. AbbVie needs to provide clear guidance about the erosion curve in Humira, its top drug (that will go off-patent next year). A popular drug going generic isn't necessarily a death sentence for the stock. He thinks management can pull this off. Sales declined only slightly, despite a 40% drop in Humira. Today, they announced a $2.2 billion settlement in opiod litigation (the opiod epidemic) which removes that overhang. It's probably a pretty good buy here.
BUY
His long-term concern comes out of Washington which is proposing drug-pricing laws. One mixed quarter doesn't worry him; the stock has been a war horse. AbbVie proves it can refill its pipeline.
Jim LebenthalOwned
0
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
